FDA Clearance Tracker · K210021
Axon Therapy
Last checked: Nov 20, 2026Latest source record: Jun 11, 2021 (this decision)Source: openFDAMethods & limitations
Decided
Jun 11, 2021
Substantially Equivalent
Time to decision
158 days
Received Jan 4, 2021. Calendar days, including time FDA spent waiting on the applicant.
Pathway
510(k)
Traditional
Device class
Class II
The decision
- FDA number
- K210021
- Device name
- Axon Therapy
- Applicant
- Neuralace Medical, Inc.
- Applicant location
- San Diego, CA
- Received
- Jan 4, 2021
- Decided
- Jun 11, 2021
- Decision
- Substantially Equivalent
- Submission type
- Traditional
Device type
- Device class
- Class II
- Regulation
- 21 CFR 882.5890
How new is this?
These are facts about FDA's records. They are not a judgment about the device.
- This is the earliest decision in FDA's data under product code QPL (Electromagnetic Stimulator, Pain Relief).
- It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.
Source documents
- FDA database record for K210021
- 510(k) summary (PDF) · FDA posts these some weeks after the decision, so a recent one may not open yet.
The predicate devices this clearance relied on are named in the summary document. We do not extract them yet.
Other decisions for Neuralace Medical, Inc.
Matched on the applicant name as FDA recorded it. A company that files under several names will have more.
- Axon Therapy510(k)
K233364 · Decided Jan 10, 2024 · 100 days after receipt
Device type: Electromagnetic Stimulator, Pain Relief (QPL) · Neurology & Neurosurgery
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.